Anti-inflammatory treatments for stroke: from bench to bedside

被引:63
|
作者
Drieu, Antoine [1 ]
Levard, Damien [1 ]
Vivien, Denis [1 ,2 ]
Rubio, Marina [1 ]
机构
[1] Normandy Univ, Pathophysiol & Imaging Neurol Disorders, Blvd Henri Becquerel BP 5229, F-14000 Caen, France
[2] CHU Caen, Imaging Neurol Disorders, Caen, France
关键词
clinical trial; immunomodulatory drugs; inflammation; stroke models; translation; ACUTE ISCHEMIC-STROKE; REGULATORY T-CELLS; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; INTERLEUKIN-1 RECEPTOR ANTAGONIST; IMMUNE MODULATOR FINGOLIMOD; SENSITIVE MOLECULAR MRI; CENTRAL-NERVOUS-SYSTEM; REDUCES BRAIN-DAMAGE; THROMBOEMBOLIC STROKE;
D O I
10.1177/1756286418789854
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of both treatments limited. Additional agents to combine with tPA administration or thrombectomy to enhance efficacy and improve outcomes associated with stroke are needed. Stroke-induced inflammatory processes are a response to the tissue damage due to the absence of blood supply but have been proposed also as key contributors to all the stages of the ischemic stroke pathophysiology. Despite promising results in experimental studies, inflammation-modulating treatments have not yet been translated successfully into the clinical setting. This review will (a) describe the timing of the stroke immune pathophysiology; (b) detail the immune responses to stroke sift-through cell type; and (c) discuss the pitfalls on the translation from experimental studies to clinical trials testing the therapeutic pertinence of immune modulators.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] From bench to bedside: novel anti-inflammatory strategies
    Occleston, Nick L.
    Knock, Amanda
    O'Kane, Sharon
    Renovo, Mark W. J. Ferguson
    [J]. WOUND REPAIR AND REGENERATION, 2008, 16 (06) : A66 - A66
  • [2] Novel Anti-inflammatory and Anti-fibrotic Agents for Diabetic Kidney Disease-From Bench to Bedside
    Nicholas, Susanne B.
    [J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 378 - 390
  • [3] New treatments for chronic inflammatory bowel disease. From bench to bedside
    Preiss, J. C.
    Duchmann, R.
    [J]. GASTROENTEROLOGE, 2007, 2 (06): : 423 - 429
  • [4] Inflammatory disease: From bench to bedside
    Byrne, Fergus R.
    [J]. AUTOIMMUNITY, 2010, 43 (07) : 461 - 462
  • [5] Anti-inflammatory treatments in sepsis
    Hoffmann, JN
    Inthorn, D
    Jauch, KW
    [J]. CHIRURG, 2003, 74 (06): : 587 - 588
  • [6] Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
    Jovani, Manol
    Fiorino, Gionata
    Danese, Silvio
    [J]. CURRENT DRUG TARGETS, 2013, 14 (12) : 1444 - 1452
  • [7] Stroke, Migraine and Triptans: From Bedside to Bench
    Raschi, Emanuel
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    [J]. EBIOMEDICINE, 2016, 6 : 14 - +
  • [8] Inflammatory Bowel Disease - From Bench to Bedside
    Fichna, Jakub
    [J]. CURRENT DRUG TARGETS, 2020, 21 (14) : 1396 - 1396
  • [9] Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: "Reverse Pharmacology" and "Bedside to Bench" Approach
    Aggarwal, Bharat B.
    Prasad, Sahdeo
    Reuter, Simone
    Kannappan, Ramaswamy
    Yadav, Vivek R.
    Park, Byoungduck
    Kim, Ji Hye
    Gupta, Subash C.
    Phromnoi, Kanokkarn
    Sundaram, Chitra
    Prasad, Seema
    Chaturvedi, Madan M.
    Sung, Bokyung
    [J]. CURRENT DRUG TARGETS, 2011, 12 (11) : 1595 - 1653
  • [10] Anti-inflammatory treatments in sepsis - Reply
    Reinhardt, K
    Bloos, F
    [J]. CHIRURG, 2003, 74 (06): : 588 - 590